Combining Compounds
A compatibility reference organized by solvent, stability, route, timing, and compound group.
Use this page as an educational reference, not as individualized medical advice. Laboratory results, monitoring decisions, contraindications, and treatment choices should be reviewed with a qualified clinician.
Why compatibility matters
Six practical factors shape compatibility between preparations. This page is a research reference, not a recommendation to combine compounds.
Water-based and oil-based preparations do not behave as one solution.
Stability can be pH-sensitive, so an acidic preparation may be incompatible with another compound even when both are water-based.
Copper, glutathione and vitamin C are highlighted because redox chemistry can affect stability.
Combining different concentrations can make measurement more error-prone.
The same route does not mean the same timing or schedule.
A mixture is only as stable as its least-stable component.
Compatibility does not mean compounds should be combined. When solvent, pH, stability, route, concentration, or timing is uncertain, keeping preparations separate is the more cautious approach.
Compatibility classifications
The classifications below organize common combinations into three practical groups: compatible under matching conditions, use extra caution, and keep separate.
One GHRH-type and one GHRP / ghrelin-type are classified as compatible when solvent, route, and schedule align. Combining two GHRPs is treated differently because their effects can overlap.
| GHRH-type | GHRP / ghrelin-type |
|---|---|
| CJC-1295 (No DAC) — short-acting | Ipamorelin — selective |
| CJC-1295 (with DAC) — long-acting | GHRP-2 — strong pulse; prolactin/cortisol + appetite caveat |
| Sermorelin — short-acting | GHRP-6 — strong pulse; hunger caveat |
| Tesamorelin — potent; visceral-fat indication | Hexarelin — strongest pulse; prolactin/cortisol caveat |
Other combinations in the MIX category: BPC-157 + TB-500; pre-made blends including GLOW, KLOW, Tri-Heal and KPV+GHK-Cu; and compatible water-based repair, mitochondrial, cognitive and longevity compounds when schedule/site context aligns. IGF-1 / MGF may still be separated because of timing rather than chemical compatibility.
| Combination | Compatibility consideration |
|---|---|
| GHK-Cu / copper peptides | Copper can oxidize sensitive peptides, making storage conditions and vitamin C important compatibility concerns. |
| BPC-157 in acetic acid | An acidic diluent can be incompatible with another peptide even when both preparations are otherwise water-based. |
| Very different concentrations | Large concentration differences can make accurate measurement more error-prone. |
| Do not co-mix | Why they are kept separate |
|---|---|
| GLP-1 / incretin agents | These agents have distinct schedules, and combining multiple GLP-1/incretin agents can compound adverse effects unless they are part of a specifically formulated combination. |
| Oil-based steroids | Oil-based preparations do not form one solution with water-based peptide preparations. |
| NAD+ / Glutathione | Volume, stability, and oxidation concerns make these poor candidates for co-mixing, including incompatibility concerns involving copper and vitamin C. |
| Different administration routes | Preparations intended for different administration routes or tissue depths should remain separate. |
Further references listed for this topic: researchdosing, peptidedosages, thepeptidereport, PubMed and NCBI Bookshelf.
Verdict by group & technique
The table below summarizes compatibility by major compound group so you can quickly see which categories are generally treated as compatible, conditional, or separate.
Growth-hormone axis
Sermorelin, Tesamorelin, CJC-1295 ±DAC, Ipamorelin, GHRP-2/6, Hexarelin, HGH, MGF/PEG-MGF, IGF-1/LR3
Water-based GH-axis compounds are grouped as compatible when solvent, route, and schedule align, although timing can still differ between compounds.
Tissue repair & recovery
BPC-157, TB-500, KPV, LL-37, B7-33, ACE-031
These are generally water-based preparations; acidic BPC-157 preparations are an important compatibility caveat.
Cognitive & neuro
DSIP, Selank, Semax, Cerebrolysin, PE-22-28, P21, Semax + Selank
Intranasal preparations remain separate from injectable preparations, and VIP is treated separately.
Longevity & bioregulators
Epithalon, Thymosin A-1, Thymalin, Humanin, Bronchogen, Vesugen, Pinealon, PNC-27
Water-based short-course compounds are grouped together when timing and route align.
Fat loss — non-GLP-1
MOTS-c, SS-31, 5-Amino-1MQ, AOD-9604, Adipotide, L-Carnitine, Lipo-C, MIC
These are grouped by shared water-based preparation, schedule, and site context.
Pre-made blends
GLOW, KLOW, Tri-Heal, Wolverine, KPV+GHK-Cu, BR226, HHB, SHB, LC120/216/526
These are already formulated as blends rather than improvised co-mixes.
Reproductive & hormonal
HCG, Kisspeptin-10/54, PT-141, Melanotan I/II, Oxytocin, Triptorelin, ACTH 1-39
Compatibility may exist, but timing and dose context vary widely; when uncertain, separation is the more cautious approach.
Aesthetic & cosmetic
Matrixyl-1, SNAP-8, AHK-Cu; Lemon Bottle; Botulinum toxin
Topicals and clinician procedures are not treated as injectable co-mixes.
Fat loss — GLP-1 / incretin
Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, Survodutide, Mazdutide, Dulaglutide, Liraglutide
These agents have their own schedules, and stacking multiple incretin agents can compound adverse effects.
Anabolic androgenic steroids
Testosterone Cypionate/Enanthate, Equipoise, Trenbolone
Oil-based preparations are kept separate from water-based peptide preparations.
Supplements & cofactors
NAD+, Glutathione, Vitamin B12, Melatonin, GHK-Cu, NAD buffer, acetic acid / BAC water
These are kept separate because of stability, oxidation, volume, or because some entries are solvents rather than dosed compounds.
Technique, sterility & troubleshooting
Key safety principles include preparing compounds separately before making a compatibility decision, maintaining aseptic handling, avoiding cross-contamination of reusable vials, avoiding storage of improvised pre-mixed preparations, following appropriate storage conditions, and discarding solutions that become cloudy, particulate, discolored, or otherwise abnormal.
This page focuses on compatibility and safety principles rather than step-by-step injection or administration instructions. Individual preparation and administration decisions should be reviewed with a qualified clinical professional.
